Reported 12 months ago
Goldman Sachs senior biotechnology analyst Chris Shibutani discusses the pharmaceutical industry, noting advancements in biotechnology innovation for unmet needs like cancer and cardiovascular disease, as well as opportunities in obesity drugs and cancer treatment. However, he warns that the Inflation Reduction Act's drug price negotiation for Medicare could challenge the industry. The act has a set protocol that will affect the entire industry, with 10 drugs initially selected for negotiation starting in 2026.
Source: YAHOO